Microbiome, Probiotics & Gut Nutrition

Biography

Biography: Sultan Gul

Abstract

Cancer is a group of diseases that is known as the second most common cause of death worldwide and has psychological and psycho-social effects on society. Significant advances have been made in cancer treatment over the past century. However, commonly used traditional treatment methods such as chemotherapy and radiotherapy have various side effects and significantly reduce the quality of life of patients. In addition, due to the difficulties experienced in the treatment of some tumor types, disease recurrence, high treatment costs and difficulties in accessing medicine, researchers have been directed to search for new treatments. In this context, it is known that actinobacteria, the most researched among prokaryotes, produce promising secondary metabolites for cancer treatment. On the other hand, secondary metabolites obtained from microorganisms and used in cancer treatment (e.g. doxorubicin) have significant side effects due to lack of targeting. In this context, integrating relevant metabolites with drug carrier systems is an effective method that can be used to eliminate treatment-related problems. In this context, within the scope of our project, the isolation of actinobacteria from soils taken from two different geographical regions of our country, the Black Sea and Central Anatolia, and their identification with the 16 S method will be carried out. Then, secondary metabolites will be obtained and purified from the isolated Actinobacter strains and their in vitro effectiveness on common cancer types such as breast cancer, lung cancer, melanoma and colorectal cancer will be determined, respectively (MCF-7), (A549), (B16F0) and (CaCo-2). ) will be investigated on cell lines. In addition, PLGA nanoformulations loaded with the obtained metabolite extracts will be produced and their effectiveness as a drug carrier system with controlled release system will be evaluated in vitro.